Blueprint Medicines Corp
BPMC
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.36B
Close$
$95.39
26.3% downside
Current Fair Value
26.3% downsideOvervalued by 26.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.36 Billion |
|---|---|
| Enterprise Value | $8.36 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.07 |
| Beta | 0.83 |
| Outstanding Shares | 63,600,000 |
Return
| Return on Equity | -45.52% |
|---|---|
| Return on Assets | -13.03% |
| Return on Invested Capital | -12.51% |
Valuation & Multiples
| P/E Ratio | -166.47 |
|---|---|
| PEG | 167.4 |
| Price to Sales | 16.18 |
| Price to Book Ratio | 25.89 |
| Enterprise Value to Revenue | 14.88 |
| Enterprise Value to EBIT | -70.73 |
| Enterprise Value to Net Income | -54 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.37 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.5691▲ 88.00% |
|---|---|
| Total Calls | 973,008▼ 36.95% |
| Total Puts | 1,526,700▲ 43.57% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 101.12%▼ 6.61% |
|---|---|
| Total Invested | $8.24B▲ 35.94% |
| Investors Holding | 379▲ 9.00% |
ESG Score
No data
About Blueprint Medicines Corp
CEO: Jeffrey Albers